Free Trial
→ One page of the SpaceX S-1 will move this stock overnight (From Behind the Markets) (Ad)tc pixel Free AGMB Stock Alerts

AgomAb Therapeutics (AGMB) Competitors

AgomAb Therapeutics logo
$11.50 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$11.44 -0.06 (-0.57%)
As of 05/22/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AGMB vs. GLUE, IOVA, ARDX, PVLA, and GHRS

Should you buy AgomAb Therapeutics stock or one of its competitors? MarketBeat compares AgomAb Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AgomAb Therapeutics include Monte Rosa Therapeutics (GLUE), Iovance Biotherapeutics (IOVA), Ardelyx (ARDX), Palvella Therapeutics (PVLA), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry.

How does AgomAb Therapeutics compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Monte Rosa Therapeutics presently has a consensus target price of $32.50, suggesting a potential upside of 72.78%. AgomAb Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 178.26%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe AgomAb Therapeutics is more favorable than Monte Rosa Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monte Rosa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
AgomAb Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

AgomAb Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. AgomAb Therapeutics' return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Monte Rosa Therapeutics-302.69% -40.99% -25.94%
AgomAb Therapeutics N/A N/A N/A

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AgomAb Therapeutics has lower revenue, but higher earnings than Monte Rosa Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monte Rosa Therapeutics$123.67M12.85-$38.63M-$1.48N/A
AgomAb TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Monte Rosa Therapeutics had 3 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 3 mentions for Monte Rosa Therapeutics and 0 mentions for AgomAb Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.00 equaled AgomAb Therapeutics'average media sentiment score.

Company Overall Sentiment
Monte Rosa Therapeutics Neutral
AgomAb Therapeutics Neutral

Summary

Monte Rosa Therapeutics and AgomAb Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Iovance Biotherapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Iovance Biotherapeutics had 3 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 3 mentions for Iovance Biotherapeutics and 0 mentions for AgomAb Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.45 beat AgomAb Therapeutics' score of 0.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
AgomAb Therapeutics Neutral
Iovance Biotherapeutics Neutral

AgomAb Therapeutics currently has a consensus target price of $32.00, suggesting a potential upside of 178.26%. Iovance Biotherapeutics has a consensus target price of $8.43, suggesting a potential upside of 105.07%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe AgomAb Therapeutics is more favorable than Iovance Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AgomAb Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Iovance Biotherapeutics
2 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.30

AgomAb Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. AgomAb Therapeutics' return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AgomAb TherapeuticsN/A N/A N/A
Iovance Biotherapeutics -123.92%-50.17%-38.77%

AgomAb Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AgomAb TherapeuticsN/AN/AN/AN/AN/A
Iovance Biotherapeutics$263.50M6.96-$390.98M-$0.95N/A

Summary

Iovance Biotherapeutics beats AgomAb Therapeutics on 6 of the 11 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

AgomAb Therapeutics has lower revenue, but higher earnings than Ardelyx.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ardelyx$407.32M3.71-$61.60M-$0.23N/A
AgomAb TherapeuticsN/AN/AN/AN/AN/A

58.9% of Ardelyx shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ardelyx presently has a consensus price target of $15.70, suggesting a potential upside of 156.96%. AgomAb Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 178.26%. Given AgomAb Therapeutics' higher possible upside, analysts clearly believe AgomAb Therapeutics is more favorable than Ardelyx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ardelyx
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.90
AgomAb Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

AgomAb Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. AgomAb Therapeutics' return on equity of 0.00% beat Ardelyx's return on equity.

Company Net Margins Return on Equity Return on Assets
Ardelyx-13.58% -38.11% -11.85%
AgomAb Therapeutics N/A N/A N/A

In the previous week, Ardelyx had 16 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 16 mentions for Ardelyx and 0 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.00 beat Ardelyx's score of -0.26 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Ardelyx Neutral
AgomAb Therapeutics Neutral

Summary

Ardelyx beats AgomAb Therapeutics on 7 of the 12 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Palvella Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

AgomAb Therapeutics' return on equity of 0.00% beat Palvella Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AgomAb TherapeuticsN/A N/A N/A
Palvella Therapeutics N/A -56.87%-42.50%

40.1% of Palvella Therapeutics shares are owned by institutional investors. 20.5% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Palvella Therapeutics had 10 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 10 mentions for Palvella Therapeutics and 0 mentions for AgomAb Therapeutics. Palvella Therapeutics' average media sentiment score of 0.29 beat AgomAb Therapeutics' score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
AgomAb Therapeutics Neutral
Palvella Therapeutics Neutral

AgomAb Therapeutics has higher earnings, but lower revenue than Palvella Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AgomAb TherapeuticsN/AN/AN/AN/AN/A
Palvella Therapeutics$42.81M38.18-$41.72M-$4.17N/A

AgomAb Therapeutics presently has a consensus price target of $32.00, indicating a potential upside of 178.26%. Palvella Therapeutics has a consensus price target of $199.53, indicating a potential upside of 75.04%. Given AgomAb Therapeutics' higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than Palvella Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AgomAb Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Palvella Therapeutics
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
1 Strong Buy rating(s)
2.94

Summary

Palvella Therapeutics beats AgomAb Therapeutics on 8 of the 11 factors compared between the two stocks.

How does AgomAb Therapeutics compare to GH Research?

AgomAb Therapeutics (NASDAQ:AGMB) and GH Research (NASDAQ:GHRS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AgomAb TherapeuticsN/AN/AN/AN/AN/A
GH ResearchN/AN/A-$48.26M-$0.92N/A

56.9% of GH Research shares are held by institutional investors. 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

AgomAb Therapeutics' return on equity of 0.00% beat GH Research's return on equity.

Company Net Margins Return on Equity Return on Assets
AgomAb TherapeuticsN/A N/A N/A
GH Research N/A -19.36%-18.73%

AgomAb Therapeutics currently has a consensus price target of $32.00, suggesting a potential upside of 178.26%. GH Research has a consensus price target of $40.38, suggesting a potential upside of 82.53%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe AgomAb Therapeutics is more favorable than GH Research.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AgomAb Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
GH Research
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73

In the previous week, GH Research had 9 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 9 mentions for GH Research and 0 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.00 beat GH Research's score of -0.86 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
AgomAb Therapeutics Neutral
GH Research Negative

Summary

AgomAb Therapeutics beats GH Research on 5 of the 9 factors compared between the two stocks.

Get AgomAb Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGMB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGMB vs. The Competition

Export
MetricAgomAb TherapeuticsBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ Exchange
Market Cap$416.73M$431.65M$4.26B$12.34B
Dividend YieldN/AN/A5.93%5.28%
P/E RatioN/AN/A21.9025.65
Price / SalesN/A326.53180.5586.31
Price / CashN/AN/A55.6856.67
Price / BookN/A3.2534.857.14
Net IncomeN/A-$81.71M$112.32M$335.98M
7 Day Performance9.42%2.74%3.52%4.15%
1 Month Performance4.07%2.02%3.56%2.54%
1 Year PerformanceN/AN/A15.78%35.06%

AgomAb Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGMB
AgomAb Therapeutics
N/A$11.50
flat		$32.00
+178.3%		N/A$416.73MN/AN/A62
GLUE
Monte Rosa Therapeutics
1.9942 of 5 stars		$17.59
-2.3%		$32.50
+84.8%		+373.8%$1.52B$123.67MN/A90
IOVA
Iovance Biotherapeutics
2.4312 of 5 stars		$3.46
+2.1%		$8.43
+143.6%		+130.9%$1.51B$263.50MN/A500
ARDX
Ardelyx
2.8803 of 5 stars		$6.09
-0.3%		$15.70
+157.8%		+53.9%$1.51B$407.32MN/A90
PVLA
Palvella Therapeutics
3.4789 of 5 stars		$109.20
+4.0%		$199.53
+82.7%		+380.6%$1.51B$42.81MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AGMB) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel